Wanzhuo He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Wanzhuo He has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Fangli Ma
Lanzhou University First Affiliated Hospital, Chengguan District, Lanzhou, China
1 shared publication - Gui-Qin Wang
Department of Lymphoma, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences Tongji Shanxi Hospital, Taiyuan, 030032, China
1 shared publication - Minghua Hu
Infinitus Chinese Herbal Immunity Research Centre, Infinitus Company Ltd, Guangzhou 510635, China
1 shared publication - Ning Tao
Department of Pathology, The affiliated Hospital, Southwest Medical University, Luzhou 646000, China; Key Laboratory of Epigenetic Regulation and Intervention, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China
1 shared publication - Wensheng Zhang
Department of Microbiology and Immunology, Shanxi Medical University, Taiyuan, China
1 shared publication Xiao Li
Beijing Institute for Drug Control, Beijing, China
1 shared publication
Latest Publications
- 13 March 2018
- Published by Wiley in Phytotherapy Research
- Vol. 32 (7) , 1297-1303
An Asparagus polysaccharide fraction inhibits MDSCs by inducing apoptosis through toll‐like receptor 4
Despite decades of research, malignant tumors are extremely difficult to eliminate with conventional methods. Although surgical resection potentially eradicates the problem, only a few cases are suitable for operation, and other approaches often involve harmful consequences. Revolutionary methods are desperately needed to improve patient outcomes and diminish harmful side effects. Myeloid‐derived suppressor cells (MDSCs), downregulators of the innate and adaptive immune systems, have been widely studied over the past 2 decades. MDSCs inhibit the antitumor immune response by suppressing T cell proliferation, cytokine production, and tumor cell killing. With MDSCs becoming novel targets in cancer therapy, our research has focused on the anti‐MDSC function of Asparagus polysaccharide (AP), extracted from asparagus, a traditional Chinese herb. In this study, we have used MDSCs isolated from the spleen of mice with colon cancer as an in vitro model to assess the efficacy of AP. Treatment of MDSCs with AP significantly decreased cell proliferation and induced apoptotic cell death through a toll‐like receptor 4 dependent way. Subsequent studies showed that the AP treatment enhanced the expression of Bax and Caspase‐9 and inhibited the expression of Bcl‐2, suggesting that AP induced apoptosis in the MDSCs via the intrinsic pathway. Altogether, the results showed that AP exhibited a significant anti‐MDSC activity and attenuated suppression of the antitumor immune response, thereby indicating its potential use in cancer therapy.
- 13 March 2018
- Published by Wiley in Phytotherapy Research
- Vol. 32 (7) , 1297-1303
An Asparagus polysaccharide fraction inhibits MDSCs by inducing apoptosis through toll‐like receptor 4
Despite decades of research, malignant tumors are extremely difficult to eliminate with conventional methods. Although surgical resection potentially eradicates the problem, only a few cases are suitable for operation, and other approaches often involve harmful consequences. Revolutionary methods are desperately needed to improve patient outcomes and diminish harmful side effects. Myeloid‐derived suppressor cells (MDSCs), downregulators of the innate and adaptive immune systems, have been widely studied over the past 2 decades. MDSCs inhibit the antitumor immune response by suppressing T cell proliferation, cytokine production, and tumor cell killing. With MDSCs becoming novel targets in cancer therapy, our research has focused on the anti‐MDSC function of Asparagus polysaccharide (AP), extracted from asparagus, a traditional Chinese herb. In this study, we have used MDSCs isolated from the spleen of mice with colon cancer as an in vitro model to assess the efficacy of AP. Treatment of MDSCs with AP significantly decreased cell proliferation and induced apoptotic cell death through a toll‐like receptor 4 dependent way. Subsequent studies showed that the AP treatment enhanced the expression of Bax and Caspase‐9 and inhibited the expression of Bcl‐2, suggesting that AP induced apoptosis in the MDSCs via the intrinsic pathway. Altogether, the results showed that AP exhibited a significant anti‐MDSC activity and attenuated suppression of the antitumor immune response, thereby indicating its potential use in cancer therapy.